Möchten Sie immer auf dem neuesten Stand bleiben?

Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training...

DUBAI, United Arab Emirates, Nov. 05, 2025 (GLOBE NEWSWIRE) -- In November 2025, MOVA officially announced the launch and trading of its native token, marking the network’s transition into full...

ENTRÉE RESOURCES ANNOUNCES THIRD QUARTER 2025 RESULTS

SANTA CLARA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AMD (NASDAQ:AMD) today announced financial results for the third quarter of 2025. Third quarter revenue was a record $9.2 billion, gross margin...

Net Income of $5.8 Million and Diluted EPS of $0.51 Per Share  Revenue of $42.0 Million, Including 93.8% Recurring Revenue Company Reiterates Expectation of Adding a New Customer in 2025 ...

Arlington, Va., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Experts from the American Institutes for Research (AIR) will present several sessions during the 2025 Association for Public Policy Analysis and...

Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Contract Research Organization (CRO) Mass Spectroscopy Services Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The...

PORTLAND, Ore., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exterro, the leading provider of Data Risk Management software, today announced that it has joined the Amazon Web Services (AWS) Independent...

Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating...

Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025 Initiated KT-621 BROADEN2 Phase 2b trial in AD ...